1. Home
  2. Blog
  3. drug safety

drug safety

Wednesday, December 4th 2013

  • Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P.  

    “Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.”

    Journal of Clinical Oncology 2017;35(13):1430-1436.  PMID: 28447913.

        Link: https://www.ncbi.nlm.nih.gov/pubmed/28447913

    The relationship between testosterone replacement therapy and prostate cancer risk is controversial. We found no association between testosterone therapy and overall prostate cancer risk. Long-term testosterone therapy was associated with a significantly reduced risk of aggressive prostate cancer.

 

  • Loeb S, Folkvaljon Y, Robinson D, Schlomm T, Garmo H, Stattin P.

    “Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.”
    European Urology. 2015 Dec 29 epub. PMID: 26743040

    Link: http://www.ncbi.nlm.nih.gov/pubmed/26743040

    A previous study from Germany reported a significantly increased risk of prostate cancer recurrence in men taking phosphodiesterase type 5 (PDE5) inhibitors after radical prostatectomy, which was subsequently refuted in an Italian study. We followed up on this issue using nationwide Swedish registry data, and confirmed that there is no association between PDE5 inhibitors with prostate cancer recurrence after treatment.

 

  • Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P.

    “Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.”

    JAMA 2015; 313: 2449-55. PMID: 26103029.

    Link: http://www.ncbi.nlm.nih.gov/pubmed/26103029

    A recent study suggested a possible link between phosphodiesterase inhibitors used for erectile dysfunction and risk of malignant melanoma.  Through a large collaboration with the national registries of Sweden, we performed a large study that raised questions about a causal relationship including lack of a dose-response relationship. Instead, the observed association between erectile dysfunction drugs and melanoma likely reflects shared risk factors including lifestyle and socioeconomic status.

 

Other Papers

  • Loeb S, Cazzaniga W, Robinson D, Garmo H, Stattin P.

    “Opiod. Use After Radical Prostatectomy: Nationwide, Population-Based Study in Sweden”

    J Urol. 2019 Jul 17 epub. PMID:31584849

    Link: https://www.ncbi.nlm.nih.gov/pubmed/31584849

 

  • Loeb S, Ventimiglia E, Salonia A, Folkvaljon Y, Stattin P.

    “Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma.”

     J Natl Cancer Inst. 2017 Aug 1;109(8). PMID: 29117385

    Link: https://www.ncbi.nlm.nih.gov/pubmed/29117385

 

  • Loeb S, Stattin P.

    “Further Evidence against a Causal Association between Erectile Dysfunction Drugs and Melanoma.”

    European Urology 2016 Jul 16 epub. PMID: 27436160.

    Link: http://www.ncbi.nlm.nih.gov/pubmed/27436160

     

 

  • Loeb S, Lambe M, Stattin P.

   “Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D.F. Penson J Urol 2015; 194: 1710-1711.”

Journal of Urology 2016 epub. PMID: 26783933

Link: http://www.ncbi.nlm.nih.gov/pubmed/26783933

 

  • Loeb S, Gupta A. Losonczy L, Tosoian J, Walsh PC.

    “Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?”

    Curr Opin Urol January 2013; 23: 2-4. PMID: 23159990.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/23159990

 

  • Loeb S.

    “Invited Editorial Comment Re: Long-Term Fluoroquinolone Use Before the Prostate Biopsy May Increase the Risk of Sepsis Caused by Resistant Microorganisms.”

    Urology August 2011; 78: 255. PMID: 21820566.

    Link: https://www.ncbi.nlm.nih.gov/pubmed/21820566

Comments are closed.